Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults

Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2015-09, Vol.136 (3), p.601-609
Hauptverfasser: Fingleton, James, PhD, Travers, Justin, MBChB, Williams, Mathew, Dip Ex Sci, Charles, Thomas, DipSM, Bowles, Darren, MBChB, Strik, Rianne, BSc, Shirtcliffe, Philippa, MBChB, Weatherall, Mark, MBChB, Beasley, Richard, DSc
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 609
container_issue 3
container_start_page 601
container_title Journal of allergy and clinical immunology
container_volume 136
creator Fingleton, James, PhD
Travers, Justin, MBChB
Williams, Mathew, Dip Ex Sci
Charles, Thomas, DipSM
Bowles, Darren, MBChB
Strik, Rianne, BSc
Shirtcliffe, Philippa, MBChB
Weatherall, Mark, MBChB
Beasley, Richard, DSc
description Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.
doi_str_mv 10.1016/j.jaci.2015.01.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717495407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674915001037</els_id><sourcerecordid>3796333671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</originalsourceid><addsrcrecordid>eNqNkl-L1TAQxYMo7nX1C_ggBV986TWTNGkDIiyL_2DBh12fQ5pOMbVtapKu9NubeleFfRBhIEz4zYEzZwh5DvQIFOTr4TgY646MgjhSyMUfkANQVZeyYeIhOVCqoJR1pc7IkxgHmnveqMfkjIm6kkrKA7m-CWjShHMqAsbFz9Hd4owxFr4vlq84-7Qt-KuL27QkP5nkbGFc-GG2_N3GFFabnJ8LNxemW8cUn5JHvRkjPrt7z8mX9-9uLj-WV58_fLq8uCqtaGQqLfLKGFAGoOGNaWxju5byihvVyU6B4VyJ3tKWtq2pGUcQXV1bYJbJqreSn5NXJ90l-O8rxqQnFy2Oo5nRr1FDDdm7qGj9PyiVggm2q768hw5-DXM2kimqWAVSskyxE2WDjzFgr5fgJhM2DVTv6ehB7-noPR1NIRfPQy_upNd2wu7PyO84MvDmBGBe263DoKN1OFvsXECbdOfdv_Xf3hu3o5udNeM33DD-9aEj01Rf7_exnwcISoHymv8EmYK1nw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709241662</pqid></control><display><type>article</type><title>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Fingleton, James, PhD ; Travers, Justin, MBChB ; Williams, Mathew, Dip Ex Sci ; Charles, Thomas, DipSM ; Bowles, Darren, MBChB ; Strik, Rianne, BSc ; Shirtcliffe, Philippa, MBChB ; Weatherall, Mark, MBChB ; Beasley, Richard, DSc</creator><creatorcontrib>Fingleton, James, PhD ; Travers, Justin, MBChB ; Williams, Mathew, Dip Ex Sci ; Charles, Thomas, DipSM ; Bowles, Darren, MBChB ; Strik, Rianne, BSc ; Shirtcliffe, Philippa, MBChB ; Weatherall, Mark, MBChB ; Beasley, Richard, DSc ; New Zealand Respiratory Health Survey Study Group</creatorcontrib><description>Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2015.01.013</identifier><identifier>PMID: 25746966</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adrenergic beta-2 Receptor Agonists - therapeutic use ; Adult ; Aged ; Airway Obstruction - complications ; Airway Obstruction - drug therapy ; Airway Obstruction - pathology ; Albuterol - therapeutic use ; Allergy and Immunology ; Anti-Asthmatic Agents - therapeutic use ; Asthma ; Asthma - complications ; Asthma - drug therapy ; Asthma - pathology ; Biomarkers ; bronchodilator ; Budesonide - therapeutic use ; Chronic obstructive pulmonary disease ; Cluster Analysis ; Disease control ; Female ; Gastroesophageal reflux ; Genotype &amp; phenotype ; Glucocorticoids - therapeutic use ; Humans ; inhaled corticosteroid ; Ipratropium - therapeutic use ; Male ; Middle Aged ; Muscarinic Antagonists - therapeutic use ; Nitric oxide ; Obesity - complications ; Obesity - drug therapy ; Obesity - pathology ; Phenotype ; Pulmonary Disease, Chronic Obstructive - complications ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - pathology ; Questionnaires ; Risk factors ; Severity of Illness Index ; Surveys and Questionnaires ; Treatment Outcome</subject><ispartof>Journal of allergy and clinical immunology, 2015-09, Vol.136 (3), p.601-609</ispartof><rights>American Academy of Allergy, Asthma &amp; Immunology</rights><rights>2015 American Academy of Allergy, Asthma &amp; Immunology</rights><rights>Copyright © 2015 American Academy of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</citedby><cites>FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</cites><orcidid>0000-0003-0337-406X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2015.01.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25746966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fingleton, James, PhD</creatorcontrib><creatorcontrib>Travers, Justin, MBChB</creatorcontrib><creatorcontrib>Williams, Mathew, Dip Ex Sci</creatorcontrib><creatorcontrib>Charles, Thomas, DipSM</creatorcontrib><creatorcontrib>Bowles, Darren, MBChB</creatorcontrib><creatorcontrib>Strik, Rianne, BSc</creatorcontrib><creatorcontrib>Shirtcliffe, Philippa, MBChB</creatorcontrib><creatorcontrib>Weatherall, Mark, MBChB</creatorcontrib><creatorcontrib>Beasley, Richard, DSc</creatorcontrib><creatorcontrib>New Zealand Respiratory Health Survey Study Group</creatorcontrib><title>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.</description><subject>Adolescent</subject><subject>Adrenergic beta-2 Receptor Agonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Airway Obstruction - complications</subject><subject>Airway Obstruction - drug therapy</subject><subject>Airway Obstruction - pathology</subject><subject>Albuterol - therapeutic use</subject><subject>Allergy and Immunology</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - complications</subject><subject>Asthma - drug therapy</subject><subject>Asthma - pathology</subject><subject>Biomarkers</subject><subject>bronchodilator</subject><subject>Budesonide - therapeutic use</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Cluster Analysis</subject><subject>Disease control</subject><subject>Female</subject><subject>Gastroesophageal reflux</subject><subject>Genotype &amp; phenotype</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>inhaled corticosteroid</subject><subject>Ipratropium - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscarinic Antagonists - therapeutic use</subject><subject>Nitric oxide</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Obesity - pathology</subject><subject>Phenotype</subject><subject>Pulmonary Disease, Chronic Obstructive - complications</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - pathology</subject><subject>Questionnaires</subject><subject>Risk factors</subject><subject>Severity of Illness Index</subject><subject>Surveys and Questionnaires</subject><subject>Treatment Outcome</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl-L1TAQxYMo7nX1C_ggBV986TWTNGkDIiyL_2DBh12fQ5pOMbVtapKu9NubeleFfRBhIEz4zYEzZwh5DvQIFOTr4TgY646MgjhSyMUfkANQVZeyYeIhOVCqoJR1pc7IkxgHmnveqMfkjIm6kkrKA7m-CWjShHMqAsbFz9Hd4owxFr4vlq84-7Qt-KuL27QkP5nkbGFc-GG2_N3GFFabnJ8LNxemW8cUn5JHvRkjPrt7z8mX9-9uLj-WV58_fLq8uCqtaGQqLfLKGFAGoOGNaWxju5byihvVyU6B4VyJ3tKWtq2pGUcQXV1bYJbJqreSn5NXJ90l-O8rxqQnFy2Oo5nRr1FDDdm7qGj9PyiVggm2q768hw5-DXM2kimqWAVSskyxE2WDjzFgr5fgJhM2DVTv6ehB7-noPR1NIRfPQy_upNd2wu7PyO84MvDmBGBe263DoKN1OFvsXECbdOfdv_Xf3hu3o5udNeM33DD-9aEj01Rf7_exnwcISoHymv8EmYK1nw</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Fingleton, James, PhD</creator><creator>Travers, Justin, MBChB</creator><creator>Williams, Mathew, Dip Ex Sci</creator><creator>Charles, Thomas, DipSM</creator><creator>Bowles, Darren, MBChB</creator><creator>Strik, Rianne, BSc</creator><creator>Shirtcliffe, Philippa, MBChB</creator><creator>Weatherall, Mark, MBChB</creator><creator>Beasley, Richard, DSc</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0337-406X</orcidid></search><sort><creationdate>20150901</creationdate><title>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</title><author>Fingleton, James, PhD ; Travers, Justin, MBChB ; Williams, Mathew, Dip Ex Sci ; Charles, Thomas, DipSM ; Bowles, Darren, MBChB ; Strik, Rianne, BSc ; Shirtcliffe, Philippa, MBChB ; Weatherall, Mark, MBChB ; Beasley, Richard, DSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adrenergic beta-2 Receptor Agonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Airway Obstruction - complications</topic><topic>Airway Obstruction - drug therapy</topic><topic>Airway Obstruction - pathology</topic><topic>Albuterol - therapeutic use</topic><topic>Allergy and Immunology</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - complications</topic><topic>Asthma - drug therapy</topic><topic>Asthma - pathology</topic><topic>Biomarkers</topic><topic>bronchodilator</topic><topic>Budesonide - therapeutic use</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Cluster Analysis</topic><topic>Disease control</topic><topic>Female</topic><topic>Gastroesophageal reflux</topic><topic>Genotype &amp; phenotype</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>inhaled corticosteroid</topic><topic>Ipratropium - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscarinic Antagonists - therapeutic use</topic><topic>Nitric oxide</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Obesity - pathology</topic><topic>Phenotype</topic><topic>Pulmonary Disease, Chronic Obstructive - complications</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - pathology</topic><topic>Questionnaires</topic><topic>Risk factors</topic><topic>Severity of Illness Index</topic><topic>Surveys and Questionnaires</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fingleton, James, PhD</creatorcontrib><creatorcontrib>Travers, Justin, MBChB</creatorcontrib><creatorcontrib>Williams, Mathew, Dip Ex Sci</creatorcontrib><creatorcontrib>Charles, Thomas, DipSM</creatorcontrib><creatorcontrib>Bowles, Darren, MBChB</creatorcontrib><creatorcontrib>Strik, Rianne, BSc</creatorcontrib><creatorcontrib>Shirtcliffe, Philippa, MBChB</creatorcontrib><creatorcontrib>Weatherall, Mark, MBChB</creatorcontrib><creatorcontrib>Beasley, Richard, DSc</creatorcontrib><creatorcontrib>New Zealand Respiratory Health Survey Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fingleton, James, PhD</au><au>Travers, Justin, MBChB</au><au>Williams, Mathew, Dip Ex Sci</au><au>Charles, Thomas, DipSM</au><au>Bowles, Darren, MBChB</au><au>Strik, Rianne, BSc</au><au>Shirtcliffe, Philippa, MBChB</au><au>Weatherall, Mark, MBChB</au><au>Beasley, Richard, DSc</au><aucorp>New Zealand Respiratory Health Survey Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>136</volume><issue>3</issue><spage>601</spage><epage>609</epage><pages>601-609</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25746966</pmid><doi>10.1016/j.jaci.2015.01.013</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0337-406X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0091-6749
ispartof Journal of allergy and clinical immunology, 2015-09, Vol.136 (3), p.601-609
issn 0091-6749
1097-6825
language eng
recordid cdi_proquest_miscellaneous_1717495407
source MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adolescent
Adrenergic beta-2 Receptor Agonists - therapeutic use
Adult
Aged
Airway Obstruction - complications
Airway Obstruction - drug therapy
Airway Obstruction - pathology
Albuterol - therapeutic use
Allergy and Immunology
Anti-Asthmatic Agents - therapeutic use
Asthma
Asthma - complications
Asthma - drug therapy
Asthma - pathology
Biomarkers
bronchodilator
Budesonide - therapeutic use
Chronic obstructive pulmonary disease
Cluster Analysis
Disease control
Female
Gastroesophageal reflux
Genotype & phenotype
Glucocorticoids - therapeutic use
Humans
inhaled corticosteroid
Ipratropium - therapeutic use
Male
Middle Aged
Muscarinic Antagonists - therapeutic use
Nitric oxide
Obesity - complications
Obesity - drug therapy
Obesity - pathology
Phenotype
Pulmonary Disease, Chronic Obstructive - complications
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - pathology
Questionnaires
Risk factors
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
title Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T01%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20responsiveness%20of%20phenotypes%20of%20symptomatic%20airways%20obstruction%20in%20adults&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Fingleton,%20James,%20PhD&rft.aucorp=New%20Zealand%20Respiratory%20Health%20Survey%20Study%20Group&rft.date=2015-09-01&rft.volume=136&rft.issue=3&rft.spage=601&rft.epage=609&rft.pages=601-609&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2015.01.013&rft_dat=%3Cproquest_cross%3E3796333671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1709241662&rft_id=info:pmid/25746966&rft_els_id=1_s2_0_S0091674915001037&rfr_iscdi=true